Saturday, 15 August 2020


Stream Bio expands its CPN products distribution network across Europe

23 October 2018 | News

The revolutionary CPNsᵀᴹ are set to transform the market with their exceptional photostability, highly specific targeting and unique magnetic core

Stream Bio Ltd, a company that develops and manufactures a range of revolutionary bioimaging molecular probes, is expanding the distribution network of its transformative Conjugated Polymer Nanoparticle (CPNTM) products across Europe. New agreements with life science distributors CliniSciences and Biotrend will make its products available for purchase in France and Germany respectively.  

Invented in the research labs of King’s College London, Stream Bio’s CPNsTMrepresent a new generation of novel molecular bioimaging probes. These highly fluorescent, non-toxic nanoparticles are set to revolutionise the bioimaging market with their unique brightness, exceptional stability, magnetic capability and suitability to be conjugated with a range of molecules.  

The novel probes have already been launched in the UK and Ireland with 2BScientific.  Distributing with CliniSciences and Biotrend, companies that market high quality products for in vitro research and diagnostics, is a major step forward for Stream Bio and its on-going plan to distribute worldwide. 

Available for purchase as of today, Stream Bio’s CPNsTMcome in four emission wavelengths 475, 510, 550 and 680 nm, covering colours blue, green, yellow and red. Stream Bio’s CPNsTMcurrently have applications in diagnostics and therapeutics and have potential to be used in tumour imaging and fluorescence-guided surgery. 

Stream Bio’s CEO, Andy Chaloner, said: “After the initial launch of our products in the UK and Ireland, we are delighted that our CPNsTM can now also be purchased in Europe. As a start-up biotech company, there is nothing better than seeing your product successfully brought to market. It’s an appreciation of all the hard work and a credit to the entire team at Stream Bio.” 

 

 


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls